Intercept Pharmaceuticals Inc RSI
Was ist das RSI von Intercept Pharmaceuticals Inc?
RSI von Intercept Pharmaceuticals Inc ist 75.79
Was ist die Definition von RSI?
Der relative Stärke-Index (RSI 14) ist ein Momentumindikator, der die Größe von Gewinnen und Verlusten über einen bestimmten Zeitraum vergleicht, um die Geschwindigkeit und die Änderung von Preisbewegungen eines Wertpapiers zu messen.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Intercept Pharmaceuticals Inc
Was macht Intercept Pharmaceuticals Inc?
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Unternehmen mit rsi ähnlich Intercept Pharmaceuticals Inc
- Kaleyra Inc hat RSI von 75.76
- Majesco hat RSI von 75.76
- Mesabi Trust hat RSI von 75.76
- Danone SA hat RSI von 75.77
- Thangamayil Jewellery hat RSI von 75.77
- Starlight U.S. Multi-Family (No. 1) Core Plus Fund hat RSI von 75.78
- Intercept Pharmaceuticals Inc hat RSI von 75.79
- 5N Plus hat RSI von 75.81
- SenSen Networks hat RSI von 75.82
- Jindal Saw hat RSI von 75.82
- Goodluck India hat RSI von 75.82
- Kerry Plc hat RSI von 75.83
- Nuvo Pharmaceuticals hat RSI von 75.84